Worth reading
20Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
1
People (increase in number of directors)Wording
Definitive
How definitive the wording is.Who is moving to which position
Resolved 28 April 2026Incoming appointee
1 itemScheduled Appointment Date26 June 2026 (formal decision scheduled to be made following approval at the Annual General Meeting of Shareholders)
Matsuo Osamu (松尾 理)
Previous positionManaging Executive Officer, General Manager of the Pharmaceuticals Business Headquarters
New positionDirector and Managing Executive Officer, General Manager of the Pharmaceuticals Business Headquarters
Shareholders’ meeting approvalRequired. Formal decision is scheduled to be made following approval at the Annual General Meeting of Shareholders scheduled for 26 June 2026.
| Item | Details |
|---|---|
| Resolution date | 28 April 2026 |
| Scheduled Appointment Date | 26 June 2026 (formal decision scheduled to be made following approval at the Annual General Meeting of Shareholders) |
| Name of appointee | Matsuo Osamu (松尾 理) |
| Appointee's new position | Director and Managing Executive Officer, General Manager of the Pharmaceuticals Business Headquarters |
| Appointee's previous position | Managing Executive Officer, General Manager of the Pharmaceuticals Business Headquarters |
| Subject to Approval by the General Meeting of Shareholders | Required. Formal decision is scheduled to be made following approval at the Annual General Meeting of Shareholders scheduled for 26 June 2026. |
Items this document does not state (15)
Date of departureAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The reason for the personnel change is not stated.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.